Aurinia Pharmaceuticals (AUPH) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Aurinia Pharmaceuticals applauds the American College of Rheumatology’s 2024 guidelines for lupus nephritis treatment, which recommend using their FDA-approved drug LUPKYNIS as part of a triple immunosuppressive therapy. The guidelines emphasize reducing steroid use and achieving specific proteinuria targets, highlighting the drug’s effectiveness demonstrated in clinical trials.
For further insights into AUPH stock, check out TipRanks’ Stock Analysis page.